Vyant Bio (VYNT) Reports In-Line Q3 EPS; Cash and Cash Equivalents of $23.2M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Vyant Bio Reports Third Quarter 2021 Results and Provides Strategic Business Updates
November 11, 2021 4:00 PM ESTStrategic Highlights
Hired Robert Fremeau, Jr., PhD as Chief Scientific Officer to lead Vyant Bios R&D programs targeting the identification of novel therapeuticsEntered into two new first phase feasibility programs with leading biopharma companies to demonstrate Vyant Bios human-derived discovery platform technology for identifying novel biological targets and novel compoundsCompleted a second large screening of artificial intelligence (AI) -generated novel compounds for Rett Syndrome, in... More